ANDSecurities Purchase Agreement • December 19th, 2003 • Skyepharma PLC • Pharmaceutical preparations • New York
Contract Type FiledDecember 19th, 2003 Company Industry Jurisdiction
Exhibit 5 VITAL LIVING, INC. REGISTRATION RIGHTS AGREEMENT This REGISTRATION RIGHTS AGREEMENT (the "Agreement"), dated as of December 15, 2003, is made by and between Vital Living, Inc., a Nevada corporation (the "Company"), and the individuals and...Registration Rights Agreement • December 19th, 2003 • Skyepharma PLC • Pharmaceutical preparations • New York
Contract Type FiledDecember 19th, 2003 Company Industry Jurisdiction
Exhibit 7 SECURITY AGREEMENT ------------------ AGREEMENT dated as of December 15, 2003, between VITAL LIVING, INC., a Nevada corporation, having an address at 5080 North 40th Street, Suite 105, Phoenix, Arizona 85018 (the "Company"), the persons and...Security Agreement • December 19th, 2003 • Skyepharma PLC • Pharmaceutical preparations • New York
Contract Type FiledDecember 19th, 2003 Company Industry Jurisdiction
VITAL LIVING, INC. 5080 N. 40th Street Suite 105 Phoenix, Arizona 85018Skyepharma PLC • December 19th, 2003 • Pharmaceutical preparations
Company FiledDecember 19th, 2003 IndustryReference is made to the Senior Secured Convertible Note (the "Note") and the Warrant (the "Warrant"), each as entered into by and between SkyePharma PLC ("SkyePharma") and Vital Living, Inc. ("Vital Living"), on the date hereof. Vital Living hereby agrees as follows, which agreements shall be in addition to its obligations with respect to delivering the Redemption Notices, as defined in each of the Note and the Warrant, contained in the Preamble, Section 4 and Section 13 of the Note and the Section 1, Section 8 and Section 12 of the Warrant, to SkyePharma. Vital Living agrees that, in the case of Redemption Notices sent pursuant to the Preamble and Section 13 of the Note and Section 8 and Section 12 of the Warrant, but not in the case of Section 4 of the Note, upon conclusion of the twenty (20) business day notice period specified in such sections, if SkyePharma has not provided written notice to Vital Living indicating that it is electing to accept the price for redemption specified